Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) two pivotal trials evaluating aflibercept 8 mg with 12- and 16-week dosing regimens met the primary…
Regeneron Pharmaceuticals Whale Trades For September 06
Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Sanofi-Regeneron’s Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) announced results from a Phase 3 open-label extension trial of Dupixent (dupilumab) as maintenance therapy…
If You Invested $100 In This Stock 20 Years Ago, You Would Have $3,900 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.59% on an annualized basis producing an average annual return of 20.17%. Currently, Regeneron Pharmaceuticals has a market capitalization of $64.04 billion.
Bluebird bio Seeks Back-to-Back Nods, ‘Go’ or ‘No-Go’ For Revance’s Botox Rival, Amylyx’ Twin Hurdles And More: September’s Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) announced results from a Phase 2 study of cemdisiran for immunoglobulin A nephropathy (IgAN). Cemdisiran is an…
Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments
The World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, with new recommendations for using…
$100 Invested In This Stock 15 Years Ago Would Be Worth $3,300 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 19.74% on an annualized basis producing an average annual return of 26.98%. Currently, Regeneron Pharmaceuticals has a market capitalization of $63.16 billion.
Regeneron’s Prostate Cancer Combo Candidate Shows Encouraging Anti-Tumor Activity
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $9.77 per share for Q2 FY22, down 62% Y/Y, beating the $9.54 estimate. Sales decreased…
Recap: Regeneron Pharmaceuticals Q2 Earnings
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q2 earnings results on Wednesday, August 3, 2022 at 06:30 AM.
Here's what investors need to know about the announcement.